Loading…
The Israeli Defense Forces Point of Injury Antimicrobial Treatment Protocol – A New Protocol and Review of the Literature
Abstract Introduction Combat wound infection is a common and serious complication, leading to significant morbidity and mortality. In 2005, a point of injury antimicrobial protocol was published by the Israel Defense Forces, in which Moxifloxacin was chosen. During 2016–2017, a revision of this prot...
Saved in:
Published in: | Military medicine 2019-03, Vol.184 (Supplement_1), p.78-82 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c393t-d52827b9160b48e6b5bb798c7e7ac3034d7acf3228bd3a115f7f919dd2b9a0b13 |
---|---|
cites | cdi_FETCH-LOGICAL-c393t-d52827b9160b48e6b5bb798c7e7ac3034d7acf3228bd3a115f7f919dd2b9a0b13 |
container_end_page | 82 |
container_issue | Supplement_1 |
container_start_page | 78 |
container_title | Military medicine |
container_volume | 184 |
creator | Glick, Yuval Furer, Ariel Glick, Karina Yitzhak, Avraham Brosh, Tal |
description | Abstract
Introduction
Combat wound infection is a common and serious complication, leading to significant morbidity and mortality. In 2005, a point of injury antimicrobial protocol was published by the Israel Defense Forces, in which Moxifloxacin was chosen. During 2016–2017, a revision of this protocol was performed and concluded with the publication of an updated protocol. The purpose of this report is to present this process and the revised protocol, together with a review of the literature.
Methods
We searched “Medline” and “Google Scholar” for studies dealing with antimicrobial prophylaxis in trauma, for militaries’ point of injury antimicrobial protocol protocols and for established surgical antimicrobial prophylaxis protocols.
Results
Point of injury antimicrobial protocol is aimed at preventing early infection and its complications. The choice of Moxifloxacin for this purpose may not be optimal since Moxifloxacin spectrum might be overly broad, there is scant evidence supporting it for this indication, and the available preparation does not meet distinctive technical requirements. Contrarily, Ceftriaxone seemed to have suitable microbiological, pharmacological and technical features.
Conclusion
Point of injury antimicrobial protocol should be used especially when evacuation and definitive surgical treatment are delayed. According to present scientific data and operational needs, Ceftriaxone was chosen for most penetrating injuries, with Metronidazole addition for penetrating abdominal and cranial trauma. |
doi_str_mv | 10.1093/milmed/usy292 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2196515813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/milmed/usy292</oup_id><sourcerecordid>2196515813</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-d52827b9160b48e6b5bb798c7e7ac3034d7acf3228bd3a115f7f919dd2b9a0b13</originalsourceid><addsrcrecordid>eNqFkUtLAzEUhYMoWqtLtxJw42Y0j3llWeqrULRIBXdDMnMHU2YmNckoxY3_wX_oLzFSpeDG1b0cPs493IPQESVnlAh-3uqmheq8dysm2BYaUMFJlFL-uI0GhLA0ikmW7KF95xaE0FjkdBftcSLCzvMBeps_AZ44K6HR-AJq6BzgK2NLcHhmdOexqfGkW_R2hUed160urVFaNnhuQfoWAjGzxpvSNPjz_QOP8C28biTZVfgeXnTQgpEPx6bag5W-t3CAdmrZODj8mUP0cHU5H99E07vryXg0jUouuI-qhOUsU4KmRMU5pCpRKhN5mUEmS054XIVZc8ZyVXFJaVJntaCiqpgSkijKh-h07bu05rkH54tWuxKaRnZgelcwKtKEJjnlAT35gy5Mb7uQrmAxJ5SQPIsDFa2p8AvnLNTF0upW2lVBSfHdSrFupVi3EvjjH9defcu_9G8Nm4SmX_7j9QVzFJlM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2430100874</pqid></control><display><type>article</type><title>The Israeli Defense Forces Point of Injury Antimicrobial Treatment Protocol – A New Protocol and Review of the Literature</title><source>Oxford Journals Online</source><creator>Glick, Yuval ; Furer, Ariel ; Glick, Karina ; Yitzhak, Avraham ; Brosh, Tal</creator><creatorcontrib>Glick, Yuval ; Furer, Ariel ; Glick, Karina ; Yitzhak, Avraham ; Brosh, Tal</creatorcontrib><description>Abstract
Introduction
Combat wound infection is a common and serious complication, leading to significant morbidity and mortality. In 2005, a point of injury antimicrobial protocol was published by the Israel Defense Forces, in which Moxifloxacin was chosen. During 2016–2017, a revision of this protocol was performed and concluded with the publication of an updated protocol. The purpose of this report is to present this process and the revised protocol, together with a review of the literature.
Methods
We searched “Medline” and “Google Scholar” for studies dealing with antimicrobial prophylaxis in trauma, for militaries’ point of injury antimicrobial protocol protocols and for established surgical antimicrobial prophylaxis protocols.
Results
Point of injury antimicrobial protocol is aimed at preventing early infection and its complications. The choice of Moxifloxacin for this purpose may not be optimal since Moxifloxacin spectrum might be overly broad, there is scant evidence supporting it for this indication, and the available preparation does not meet distinctive technical requirements. Contrarily, Ceftriaxone seemed to have suitable microbiological, pharmacological and technical features.
Conclusion
Point of injury antimicrobial protocol should be used especially when evacuation and definitive surgical treatment are delayed. According to present scientific data and operational needs, Ceftriaxone was chosen for most penetrating injuries, with Metronidazole addition for penetrating abdominal and cranial trauma.</description><identifier>ISSN: 0026-4075</identifier><identifier>EISSN: 1930-613X</identifier><identifier>DOI: 10.1093/milmed/usy292</identifier><identifier>PMID: 30901438</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Anti-Bacterial Agents - therapeutic use ; Antibiotics ; Antimicrobial agents ; Guidelines as Topic ; Humans ; Israel ; Military Medicine - trends ; Point-of-Care Systems - trends ; Protocol ; Trauma ; Wounds and Injuries - drug therapy</subject><ispartof>Military medicine, 2019-03, Vol.184 (Supplement_1), p.78-82</ispartof><rights>Association of Military Surgeons of the United States 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2019</rights><rights>Association of Military Surgeons of the United States 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-d52827b9160b48e6b5bb798c7e7ac3034d7acf3228bd3a115f7f919dd2b9a0b13</citedby><cites>FETCH-LOGICAL-c393t-d52827b9160b48e6b5bb798c7e7ac3034d7acf3228bd3a115f7f919dd2b9a0b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30901438$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Glick, Yuval</creatorcontrib><creatorcontrib>Furer, Ariel</creatorcontrib><creatorcontrib>Glick, Karina</creatorcontrib><creatorcontrib>Yitzhak, Avraham</creatorcontrib><creatorcontrib>Brosh, Tal</creatorcontrib><title>The Israeli Defense Forces Point of Injury Antimicrobial Treatment Protocol – A New Protocol and Review of the Literature</title><title>Military medicine</title><addtitle>Mil Med</addtitle><description>Abstract
Introduction
Combat wound infection is a common and serious complication, leading to significant morbidity and mortality. In 2005, a point of injury antimicrobial protocol was published by the Israel Defense Forces, in which Moxifloxacin was chosen. During 2016–2017, a revision of this protocol was performed and concluded with the publication of an updated protocol. The purpose of this report is to present this process and the revised protocol, together with a review of the literature.
Methods
We searched “Medline” and “Google Scholar” for studies dealing with antimicrobial prophylaxis in trauma, for militaries’ point of injury antimicrobial protocol protocols and for established surgical antimicrobial prophylaxis protocols.
Results
Point of injury antimicrobial protocol is aimed at preventing early infection and its complications. The choice of Moxifloxacin for this purpose may not be optimal since Moxifloxacin spectrum might be overly broad, there is scant evidence supporting it for this indication, and the available preparation does not meet distinctive technical requirements. Contrarily, Ceftriaxone seemed to have suitable microbiological, pharmacological and technical features.
Conclusion
Point of injury antimicrobial protocol should be used especially when evacuation and definitive surgical treatment are delayed. According to present scientific data and operational needs, Ceftriaxone was chosen for most penetrating injuries, with Metronidazole addition for penetrating abdominal and cranial trauma.</description><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Guidelines as Topic</subject><subject>Humans</subject><subject>Israel</subject><subject>Military Medicine - trends</subject><subject>Point-of-Care Systems - trends</subject><subject>Protocol</subject><subject>Trauma</subject><subject>Wounds and Injuries - drug therapy</subject><issn>0026-4075</issn><issn>1930-613X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqFkUtLAzEUhYMoWqtLtxJw42Y0j3llWeqrULRIBXdDMnMHU2YmNckoxY3_wX_oLzFSpeDG1b0cPs493IPQESVnlAh-3uqmheq8dysm2BYaUMFJlFL-uI0GhLA0ikmW7KF95xaE0FjkdBftcSLCzvMBeps_AZ44K6HR-AJq6BzgK2NLcHhmdOexqfGkW_R2hUed160urVFaNnhuQfoWAjGzxpvSNPjz_QOP8C28biTZVfgeXnTQgpEPx6bag5W-t3CAdmrZODj8mUP0cHU5H99E07vryXg0jUouuI-qhOUsU4KmRMU5pCpRKhN5mUEmS054XIVZc8ZyVXFJaVJntaCiqpgSkijKh-h07bu05rkH54tWuxKaRnZgelcwKtKEJjnlAT35gy5Mb7uQrmAxJ5SQPIsDFa2p8AvnLNTF0upW2lVBSfHdSrFupVi3EvjjH9defcu_9G8Nm4SmX_7j9QVzFJlM</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Glick, Yuval</creator><creator>Furer, Ariel</creator><creator>Glick, Karina</creator><creator>Yitzhak, Avraham</creator><creator>Brosh, Tal</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>4T-</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20190301</creationdate><title>The Israeli Defense Forces Point of Injury Antimicrobial Treatment Protocol – A New Protocol and Review of the Literature</title><author>Glick, Yuval ; Furer, Ariel ; Glick, Karina ; Yitzhak, Avraham ; Brosh, Tal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-d52827b9160b48e6b5bb798c7e7ac3034d7acf3228bd3a115f7f919dd2b9a0b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Guidelines as Topic</topic><topic>Humans</topic><topic>Israel</topic><topic>Military Medicine - trends</topic><topic>Point-of-Care Systems - trends</topic><topic>Protocol</topic><topic>Trauma</topic><topic>Wounds and Injuries - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Glick, Yuval</creatorcontrib><creatorcontrib>Furer, Ariel</creatorcontrib><creatorcontrib>Glick, Karina</creatorcontrib><creatorcontrib>Yitzhak, Avraham</creatorcontrib><creatorcontrib>Brosh, Tal</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Docstoc</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Military medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Glick, Yuval</au><au>Furer, Ariel</au><au>Glick, Karina</au><au>Yitzhak, Avraham</au><au>Brosh, Tal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Israeli Defense Forces Point of Injury Antimicrobial Treatment Protocol – A New Protocol and Review of the Literature</atitle><jtitle>Military medicine</jtitle><addtitle>Mil Med</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>184</volume><issue>Supplement_1</issue><spage>78</spage><epage>82</epage><pages>78-82</pages><issn>0026-4075</issn><eissn>1930-613X</eissn><abstract>Abstract
Introduction
Combat wound infection is a common and serious complication, leading to significant morbidity and mortality. In 2005, a point of injury antimicrobial protocol was published by the Israel Defense Forces, in which Moxifloxacin was chosen. During 2016–2017, a revision of this protocol was performed and concluded with the publication of an updated protocol. The purpose of this report is to present this process and the revised protocol, together with a review of the literature.
Methods
We searched “Medline” and “Google Scholar” for studies dealing with antimicrobial prophylaxis in trauma, for militaries’ point of injury antimicrobial protocol protocols and for established surgical antimicrobial prophylaxis protocols.
Results
Point of injury antimicrobial protocol is aimed at preventing early infection and its complications. The choice of Moxifloxacin for this purpose may not be optimal since Moxifloxacin spectrum might be overly broad, there is scant evidence supporting it for this indication, and the available preparation does not meet distinctive technical requirements. Contrarily, Ceftriaxone seemed to have suitable microbiological, pharmacological and technical features.
Conclusion
Point of injury antimicrobial protocol should be used especially when evacuation and definitive surgical treatment are delayed. According to present scientific data and operational needs, Ceftriaxone was chosen for most penetrating injuries, with Metronidazole addition for penetrating abdominal and cranial trauma.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>30901438</pmid><doi>10.1093/milmed/usy292</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0026-4075 |
ispartof | Military medicine, 2019-03, Vol.184 (Supplement_1), p.78-82 |
issn | 0026-4075 1930-613X |
language | eng |
recordid | cdi_proquest_miscellaneous_2196515813 |
source | Oxford Journals Online |
subjects | Anti-Bacterial Agents - therapeutic use Antibiotics Antimicrobial agents Guidelines as Topic Humans Israel Military Medicine - trends Point-of-Care Systems - trends Protocol Trauma Wounds and Injuries - drug therapy |
title | The Israeli Defense Forces Point of Injury Antimicrobial Treatment Protocol – A New Protocol and Review of the Literature |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T07%3A47%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Israeli%20Defense%20Forces%20Point%20of%20Injury%20Antimicrobial%20Treatment%20Protocol%20%E2%80%93%20A%20New%20Protocol%20and%20Review%20of%20the%20Literature&rft.jtitle=Military%20medicine&rft.au=Glick,%20Yuval&rft.date=2019-03-01&rft.volume=184&rft.issue=Supplement_1&rft.spage=78&rft.epage=82&rft.pages=78-82&rft.issn=0026-4075&rft.eissn=1930-613X&rft_id=info:doi/10.1093/milmed/usy292&rft_dat=%3Cproquest_cross%3E2196515813%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c393t-d52827b9160b48e6b5bb798c7e7ac3034d7acf3228bd3a115f7f919dd2b9a0b13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2430100874&rft_id=info:pmid/30901438&rft_oup_id=10.1093/milmed/usy292&rfr_iscdi=true |